Seed, Scaffold and Signal as clinical communication

The communication problem multi-component therapy creates

When a clinical technique combines three biological components, a predictable misreading follows: patients and clinicians alike tend to search for the active ingredient — the one element carrying the real therapeutic load, with the others playing a supporting role. In a single-component treatment, this instinct is harmless. In a three-part biological protocol, it is a communication failure that can undermine the logic of the entire approach.

This is the challenge Professor Paul Lee faced in communicating NanoACi™. Each of its three components — a cellular seed, a retaining scaffold and a biological signal — has published evidence behind it. Yet none of the three is independently sufficient. Describing them in sequence, however clearly, risks implying a hierarchy that does not exist.

The Seed, Scaffold and Signal framework was built to solve that problem. Rather than listing what each element is, the framework assigns each one a specific failure mode it corrects — making the combination legible not as a bundle of options but as the minimum complete unit a joint needs to attempt repair.

Three failure modes, three roles — and why the combination is the minimum complete unit

Cartilage fails to repair itself for three distinct reasons, and the Seed, Scaffold and Signal framework addresses each one in turn.

Without chondrogenic cells at the damage site, no new cartilage matrix can form. The framework provides the Seed: autologous micrografts prepared chair-side from three 2.5-millimetre punches taken from the concha of the patient's ear under local anaesthetic. Ear cartilage is derived from the neural crest rather than mesoderm — its cells are HOX-negative, meaning they carry no fixed positional identity codes. Published research from a Basel group demonstrated that adult human neural-crest-derived cartilage cells can read a joint environment and adopt joint identity, making them genuinely adaptable to the repair site rather than merely transplanted bystanders.

Without something to hold those cells at the defect, they disperse on delivery and the opportunity is lost. The framework provides the Scaffold: ChondroFiller, a cell-free native type I collagen matrix that self-assembles into a three-dimensional mesh, trapping the ear-derived cells in place at the site of damage in a structure they can live and build within. ChondroFiller carries CE marking (gel form, 2012; injectable liquid, 2013), providing a regulatory baseline for the scaffold's safety and performance profile.

Without a biological instruction set, the retained cells have no trigger to begin chondrogenic activity. The framework provides the Signal: Arthrozheal, autologous platelet-rich fibrin prepared chair-side from the patient's own blood in the same sitting. It serves simultaneously as a carrier medium and a sustained source of growth factors directing the cells towards cartilage production.

All three are combined and delivered through a single needle in one planned sitting, with no cell-culture stage, no general anaesthetic and no arthroscopy. The clinical consequence is that the minimum complete biological unit and the simplest possible delivery route are the same procedure.

The agricultural metaphor and what it keeps legible for patients

Professor Lee's own description of NanoACi is deliberately domestic: 'not a product but a recipe — seed, soil, and fertiliser, combined and delivered through a single needle.' The choice of register is purposeful. Agricultural growth is one of the oldest intuitive models people hold — a seed needs somewhere to root, and something to make it grow — and that model arrives in the reader's mind already assembled. The metaphor does not ask them to learn a new structure; it asks them to recognise one they already have.

What that recognition does, practically, is transfer the necessity argument without a biology lesson. Once a patient accepts that a seed without soil blows away, and soil without fertiliser sits inert, the three-part logic of the protocol becomes self-evident — and so does the consequence of removing any element. A patient who has internalised 'seed, soil, fertiliser' can reason independently about what a partial protocol would be missing: cells without a scaffold to retain them, or a scaffold with no cells to populate it. The question 'what would I be getting if I only had two of the three?' answers itself, which is precisely what well-chosen clinical communication is supposed to achieve.

This is why 'accessible' is not the same as 'simplified.' The metaphor does not shorten the science; it reframes a three-variable argument in a register that patients can test and interrogate rather than simply accept. The completeness — all three, or the minimum is not met — is the point the clinical language and the agricultural language are making in exactly the same breath.

How the framework carries independent clinical credibility

For a clinician, the Seed/Scaffold/Signal map names three categories already present in the standard biological vocabulary of repair: cell source, extracellular matrix, and growth-factor signalling. Each has its own evidence body, and the framework assigns one to each component.

The Seed draws on two converging evidence bases. Neural-crest biology — developed in part through Basel-group research showing that HOX-negative adult human chondrocytes can read and adopt joint-environment identity — underpins the selection of auricular cartilage over donor-site alternatives. ENT and plastic surgery have documented decades of safe ear-to-nose cartilage harvesting, establishing clinical precedent that sits entirely outside regenerative medicine claims.

The Scaffold, ChondroFiller, carries more than a decade of multi-joint use across knee, hip, thumb and wrist, exceeding 20,000 implantations. The key bridge study is Weninger et al. (2025), which reported the scaffold in combination with autologous cells in Grade IV knee defects — the closest published approximation to the full NanoACi protocol, and the evidence most directly relevant to clinicians assessing end-stage presentations. The Signal component, Arthrozheal PRF, has independent published support for its growth-factor profile and fibrin matrix behaviour: Lundquist et al. (2008), Ågren et al. in Vox Sanguinis (2014), and Peset (2020) on knee osteoarthritis application.

Combined-protocol outcomes for the three-part technique are being built through NanoACi 100: one hundred consecutive cases with pre-agreed pain, function and imaging measures at fixed intervals, results withheld until the dataset is complete. The current evidence position — component evidence is established; combined randomised data are in progress — is a single sentence, and it is the sentence a clinician would reach for anyway.

RegenRepair, PRRR and where NanoACi sits in the treatment landscape

The Seed/Scaffold/Signal architecture extends beyond cartilage under the RegenRepair™ brand, which applies the same three-role logic to four tissue-specific pathways: NanoACi for cartilage, NanoAMi for meniscus, NanoATi for tendon and NanoALi for ligament. Because the conceptual vocabulary stays fixed — cell source, retention matrix, growth-factor signal — a referring clinician who understands the cartilage pathway needs no new framework to understand the others. The clinical details change according to the tissue, damage pattern and mechanical demands; the architecture does not.

Within the cartilage pathway, PRRR (Preserve, Repair, Regenerate, Replace) supplies the routing signal that locates NanoACi's patient population. The Regenerate step falls between focal repair — which requires a contained, accessible defect — and joint replacement, which surrenders the native joint entirely. Patients past the first and not yet at the second occupy a clinically recognised gap, and naming it gives both patients and referring clinicians a clear decision point rather than a loose spectrum.

STACi provides the framework's surgical exception, mapping the boundary explicitly: where joint alignment or instability must be corrected before biology can work, surgery becomes part of the treatment logic rather than an alternative to it. Including this defined exit point gives the framework explicit scope rather than an unqualified reach, which adds rather than subtracts credibility.

The maintenance model sets the temporal register. Rather than a single intervention event, NanoACi belongs to a programme of planned biological assessments and repeat procedures calibrated to the joint's changing needs over time — a category of care closer to long-term joint management than to one-off surgical repair, and one that patients and clinicians can plan for rather than simply await.

Why the framework's clarity is itself part of the clinical case

Communicability and clinical design rarely share the same architecture. In NanoACi they do, and that co-extension is the framework's deepest argument.

When a patient can trace each component to the failure mode it corrects, they are not absorbing a simplified version of a complex procedure — they are following the procedure's own logic. The Seed/Scaffold/Signal structure is not laid over the protocol as explanation: it is the protocol made legible. A patient or clinician who has tracked the three-failure-mode argument can identify, from first principles, why a partial protocol falls short — and what is absent from it. That reasoning capacity is what genuine informed consent requires, rather than performed.

The minimum-complete-unit framing carries a second practical effect. Comparison between NanoACi and its component parts — scaffold alone, cells alone — is not a competitive manoeuvre but the same deficit logic applied comparatively. A clinician or patient who understands what each role contributes can assess any cartilage protocol against the same three-part checklist, which is protective rather than promotional.

For patients arriving at a case review with Professor Lee, the framework has already done useful work. They know what will be prepared, what role each element plays, and what question the ongoing NanoACi 100 programme is designed to answer. Informed choice can begin before the consultation, not during it.